Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Israeli neonatal herpes simplex infection: Unique epidemiology and clinical profile.
J Med Virol
September 2024
Pediatric Infectious diseases Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Article Synopsis
- A study conducted on Israeli neonatal herpes simplex virus (NHSV) infection collected data from 2015 to 2022, comparing clinical characteristics of NHSV patients with those suffering from neonatal enteroviral meningitis (NEM).
- The results showed an NHSV incidence of 5.9 per 100,000 live births, with notable demographics suggesting that horizontal transmission was linked to practices like ritual circumcision.
- NHSV patients presented unique symptoms such as a lower incidence of fever and irritability but showed a tendency for rashes and seizures, marking a distinct clinical profile compared to NEM, which can help guide treatment approaches for infected newborns.
A drug repurposing screen identifies decitabine as an HSV-1 antiviral.
Microbiol Spectr
November 2024
The Department of Molecular Biology and Biochemistry, The University of California Irvine, Irvine, California, USA.
Unlabelled: Herpes simplex virus type 1 (HSV-1) is a highly prevalent human pathogen that causes a range of clinical manifestations, including oral and genital herpes, keratitis, encephalitis, and disseminated neonatal disease. Despite its significant health and economic burden, there is currently only a handful of approved antiviral drugs to treat HSV-1 infection. Acyclovir and its analogs are the first-line treatment, but resistance often arises during prolonged treatment periods, such as in immunocompromised patients.
View Article and Find Full Text PDFEfgartigimod-associated Kaposi's varicelliform eruption and herpetic conjunctivitis in a patient with seropositive ocular myasthenia gravis: a case report and review.
Front Immunol
August 2024
Department of Dermatology, The Second Affiliated Hospital of Shandong First Medical University, Tai'an, China.
Article Synopsis
- Efgartigimod (Vyvgart™) is a new drug for treating severe autoimmune diseases like myasthenia gravis by targeting pathogenic IgG autoantibodies, with generally mild side effects.
- A case study describes a 60-year-old man with ocular myasthenia gravis who developed Kaposi's varicelliform eruption and herpetic conjunctivitis after receiving efgartigimod, showing symptoms like fever and painful blisters.
- This incident marks the first reported case of such side effects related to efgartigimod, highlighting the need for healthcare professionals to be aware of these unusual reactions.
High silent prevalence of human herpesvirus 1 (HSV-1) infection affecting the indigenous reservation of the municipality of Dourados, Central-West Brazil.
BMC Infect Dis
July 2024
Molecular Virology and Parasitology Laboratory, Oswaldo Cruz Foundation, Rio de Janeiro, 21040360, Brazil.
Article Synopsis
- * A cross-sectional approach was used, enrolling 1,138 individuals over nearly two years, with tests revealing a 20% prevalence of IgM antibodies and a remarkable 97.5% for IgG antibodies against HSV-1.
- * The presence of HSV-1 DNA was confirmed in over a quarter of individuals with positive IgM results, indicating a significant silent prevalence of the virus within this community, particularly in individuals with certain urinary and genital symptoms.
Introduction And Importance: The herpes simplex virus (HSV) is the most common cause of acute sporadic encephalitis, a severe and often fatal disease in humans. It is associated with high mortality and morbidity rates in untreated patients.
Case Presentation: An 11-month-old child was admitted to the hospital presenting with acute fever and seizures characterized by staring episodes and spastic movements affecting the left side of the body.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!